This article is more than 5 years old. Information may no longer be current.
Intra-articular LMWF-5A seen as safe, effective treatment for knee OA
Click Here to Manage Email Alerts
Patients with osteoarthritis of the knee who received repeated intra-articular injections of low-molecular-weight fraction of 5% human serum albumin experienced pain relief at 20 weeks, according to results.
John Schwappach , MD, and colleagues randomly assigned 40 patients with osteoarthritis (OA) of the knee to receive three biweekly intra-articular knee injections of either 4 mL low-molecular-weight fraction of 5% human serum albumin (LMWF-5A) or saline administered at baseline, 2 weeks and 4 weeks. Researchers examined safety as the incidence and severity of adverse events and assessed efficacy by the mean change between treatment groups in the WOMAC pain score from baseline to week 20.
Results showed no patients experienced drug-related serious adverse events or death. Researchers noted similar adverse events between the LMWF-5A group and the saline group. Compared with the saline group, researchers found a significant decrease in pain at 20 weeks among patients treated with LMWF-5A. This corresponded with an improvement in pain of 64% with LMWF-5A vs. 40% with saline at 20 weeks. – by Casey Tingle
Disclosures: Schwappach’s institution has received consulting fees from Ampio Pharmaceuticals Inc. Please see the full study for a list of all other authors’ relevant financial disclosures.
Click Here to Manage Email Alerts